Kits and reagents represent 60.9% within the component segment and synthesis sequencing accounts for 68.5% of the technology category in 2025. The clinical oncology next-generation sequencing market was valued at USD 744.4 million in 2025 and is forecast to post a 17.3% CAGR between 2025 and 2035.